MedTrace Logo

Intra-venous Zoledronic Acid Once Yearly

NCT00984893 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1551

Last updated 2016-03-04

No results posted yet for this study

Summary

The study will assess the real life effectiveness of zoledronic acid in the management of patients with osteoporosis over 4 years of treatment. Zoledronic acid will be compared to oral bisphosphonates (OBP) with respect to the change in Bone Mineral Density (BMD) and incidence of fractures.

Conditions

  • Post-Menopausal Osteoporosis

Interventions

DRUG

zoledronic acid

DRUG

Any oral bisphosphonates marketed in Canada

Sponsors & Collaborators

Principal Investigators

  • Marc Vaillancourt · Novartis Pharmaceuticals Canada

Eligibility

Min Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00984893 on ClinicalTrials.gov